NEW YORK, December 31, 2025, 5:04 PM ET — After-hours
- INBS closed up 132% at $9.53 and slipped 6% to $8.95 after the bell.
- Company said a new manufacturing partnership aims for more than 40% production cost savings and a roughly 20-point gross margin lift.
- Traders are watching execution on the supply shift and whether the stock can sustain levels needed to clear a Nasdaq bid-price deficiency.
Shares of Intelligent Bio Solutions Inc more than doubled in Wednesday’s regular session as investors piled into the micro-cap medical technology stock on a fresh manufacturing update.
The stock closed at $9.53, up $5.43 from Tuesday’s close of $4.10, and traded at $8.95 in after-hours dealings. The shares ranged from $5.62 to $12.94 on the day, giving the company a market value of about $9 million. Google
The rally matters because manufacturing economics are a pressure point for small diagnostics and testing-device makers. Investors want proof that scaling hardware production can widen margins, not just raise costs.
In thinly traded micro-caps, sharp moves are common, but the size of the jump puts a spotlight on whether the company can convert an operational headline into measurable margin improvement over coming quarters.
Intelligent Bio Solutions said it struck a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader. The company said it expects more than 40% annual production cost savings and an improvement of about 20 percentage points in gross margin — the share of revenue left after production costs — while Syrma Johari’s capacity is about four times its current output. “Partnering with Syrma Johari is a strategically significant milestone for our business,” Callistus Sequeira, vice president of global quality and operations, said in the statement. Intelligent Bio Solutions Inc.
Manufacturing switches can take time to deliver savings, especially for regulated devices that require strict quality controls. Investors will look for timelines on qualification work, steady product supply and evidence the savings flow through to reported results.
Nasdaq listing compliance is another near-term overhang. A December 15 filing said the company received a Nasdaq notice after its closing bid price stayed below $1 for 30 consecutive business days, and it has until June 15, 2026 to regain compliance, typically by holding a $1 bid for at least 10 straight sessions. The filing also said the company effected a 1-for-10 reverse stock split — which reduces the share count while lifting the per-share price without changing the company’s overall value — effective late December 15, with split-adjusted trading beginning December 16. SEC
Wednesday’s close leaves the stock well above the $1 threshold, but the next question is durability. Sustained closes, not one-day spikes, determine whether a deficiency flag comes off.
The company’s most recent quarterly update in November showed how sensitive the story is to margin trends. It reported fiscal first-quarter revenue of $1.11 million and said gross profit margin rose to 46.6%, with cartridge sales accounting for nearly 58% of total revenue. Intelligent Bio Solutions
That mix matters because recurring consumable sales tend to carry higher margins than hardware. Investors will be watching whether manufacturing scale supports faster reader deployments without compressing cartridge profitability.
The next catalyst is likely the company’s next quarterly report, which should capture early impacts from any supply-chain or production changes. Any update to the timing of a planned U.S. market entry — and the regulatory steps needed to support it — is also likely to move the stock given its size.
After-hours weakness suggests some traders took profits quickly, a common pattern in small-cap momentum names. The stock’s wide intraday range underscores the risk of sharp reversals if follow-through buying fades.
U.S. stock markets are closed on Thursday for New Year’s Day and will reopen on Friday, January 2, which could leave the next price test for INBS to a thinner, early-January tape. Nasdaq
